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The 14-kDa Vpr protein of human immunodeficiency virus type 1 (HIV-1) serves multiple functions in the retroviral life cycle,
including the enhancement of viral replication in nondividing macrophages, the induction of G2 cell-cycle arrest in prolifer-
ating T lymphocytes, and the modulation of HIV-1-induced apoptosis. Extracellular Vpr has been detected in the sera and
cerebral spinal fluid of HIV-infected patients. However, it is not known whether such forms of Vpr are biologically active. Vpr
contains a carboxy-terminal basic amino acid rich segment stretch that is homologous to domains that mediate the energy-
and receptor-independent cellular uptake of polypeptides by a process termed protein transduction. Similar functional
protein-transducing domains are present in HIV-1 Tat, herpes simplex virus-1 DNA-binding protein VP22, and the Drosophila
antennapedia homeotic transcription factor. We now demonstrate effective transduction of biologically active, synthetic Vpr
(sVpr) as well as the Vpr--galactosidase fusion protein. However, in contrast to other transducing proteins, Vpr transduction
is not enhanced by protein denaturation, and Vpr’s carboxy-terminal basic domain alone is not sufficient for its transduction
across biological membranes. In contrast, the full-length Vpr protein effectively transduces a broad array of cells, leading to
dose-dependent G2 cell-cycle arrest and apoptosis. Addition of Vpr into the extracellular medium also rescues the replication
of Vpr-deficient strains of HIV-1 in human macrophage cultures. Native Vpr may thus be optimized for protein transduction,Key Words: protein transduction; HIV; Vpr; cell cycle.
INTRODUCTION
In addition to the genes encoding the structural and
enzymatic proteins common to all retroviruses, the hu-
man immunodeficiency virus type 1 (HIV-1) genome con-
tains four accessory genes that serve to accelerate viral
replication. One of these gene products, viral protein R
(Vpr), is a 96 amino acid polypeptide that is packaged
into progeny virions through its interaction with the car-
boxy-terminal p6Gag domain of the Pr55Gag precursor pro-
tein (Cohen et al., 1990; Paxton et al., 1993; Yuan et al.,
1990). HIV-1 Vpr is highly conserved in vivo (Goh et al.,
1998; Yedavalli et al., 1998). In the HIV-2 and simian
immunodeficiency primate lentiviruses, the function of
HIV-1 Vpr is divided between two related proteins, Vpr2
and Vpx (Campbell and Hirsch, 1997; Gibbs and Desro-
siers, 1993). Vpr induces G2 cell-cycle arrest in HIV-1-
infected and/or Vpr-transfected proliferating human cells
(Bartz et al., 1996; Goh et al., 1998; He et al., 1995;
Hrimech et al., 1999; Jowett et al., 1995; Poon et al., 1998;
1 The first three authors contributed equally to this paper.
2 To whom correspondence and reprint requests should be ad-
dressed at Gladstone Institute of Virology and Immunology, P.O. Box95Re et al., 1995), likely through alterations in the nuclear
lamina of cells that lead to dynamic herniations and
rupture of the nuclear envelope (de Noronha et al., 2001).
Arrest in the G2 phase of the cell cycle provides an
intracellular milieu conducive for increased HIV LTR ac-
tivity and thus viral replication (Goh et al., 1998). Other
studies suggest that the prolonged G2 arrest induced by
Vpr ultimately leads to apoptosis of the infected cell
(Poon et al., 1998; Stewart et al., 1997, 1999, 2000; Yao et
al., 1998). Conversely, early antiapoptotic effects of Vpr
have also been described which are supplanted later by
its proapoptotic effects (Conti et al., 2000). These pro-
apoptotic effects of Vpr may result from direct mitochon-
drial membrane permeabilization (Ferri et al., 2000), a
function that implies the penetration of cellular mem-
branes by Vpr (Piller et al., 1999).
Vpr is principally localized in the nucleus despite the
lack of any canonical lysine-rich nuclear import signal
(Gallay et al., 1996, 1997; Lu et al., 1993). We and others
have recently shown that Vpr contains at least two dis-
tinct and novel nuclear localization signals (Jenkins et al.,
1998; Karni et al., 1998; Sherman et al., 2000). Further, Vpr
displays nucleocytoplasmic shuttling properties reflect-a feature that might enhance and extend the pathological
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properties of Vpr are thought to contribute to HIV-1 in-
fection of macrophages (Bukrinsky et al., 1992; Connor et
al., 1995; Heinzinger et al., 1994; Miller et al., 1997; Popov
et al., 1998). In this regard, although Vpr is not required
for HIV-1 infection of nondividing resting T cells (Eckstein
et al., 2001), HIV encodes at least three karyophilic pro-
teins including Vpr, matrix p17MA, and integrase that have
been variably proposed to play a role in nuclear uptake
of the large viral preintegration complex (PIC, Stokes
diameter of 56 nm) (Bouyac-Bertoia et al., 2001; Bukrin-
sky et al., 1993; Fouchier et al., 1997; Gallay et al., 1996,
1997; Petit et al., 2000; van Schwedler et al., 1994). In
addition, a triple-stranded DNA flap formed as an inter-
mediate of reverse transcription may also contribute to
nuclear uptake of the viral PIC (Zennou et al., 2000).
Structural studies of fragments of Vpr (Luo et al., 1998;
Wecker and Roques, 1999) or, more recently, full-length
Vpr (Henklein et al., 2000) suggest the presence of a
helix-turn-helix between residues 17 and 49 and an am-
phipathic helix between residues 53 and 78. These he-
lices likely play a key role in homodimerization and the
interaction of Vpr with heterologous proteins (Henklein et
al., 2000; Zhao et al., 1994a,b). Both helical domains are
highly conserved (Sherman et al., 2000) and contribute to
the formation of a novel nuclear import signal. The distal
helix also contains leucine-rich nuclear export signal
whose function is inhibited by leptomycin B (Sherman et
al., 2001). The carboxy-terminal region of Vpr contains a
basic amino acid rich segment between residues 73 and
96 for which no definite structure has been assigned
(Schuler et al., 1999). However, this region is conserved
and influences the stability and, potentially, the structure
of the entire protein (Yao et al., 1995). This carboxy-
terminal domain also contains a bipartite, arginine-rich
nuclear import signal that can promote nuclear uptake of
heterologous proteins through the nuclear pore complex
(Jenkins et al., 1998; Sherman et al., 2001).
Despite the limiting lipid bilayer comprising the
plasma membrane of eukaryotes, an increasing number
of proteins have been found to cross this membrane in
an apparently energy- and receptor-independent man-
ner. This process—termed protein transduction (Frankel
and Pabo, 1988; Green and Loewenstein, 1988) [for re-
views, see Hawiger (1999); Porchiantz (2000); Schwarze
and Dowdy (2000); Schwarze et al., (2000)]—relies upon
the presence of an arginine-rich protein transduction
domain (PTD). The carboxy-terminal arginine-rich region
of Vpr strongly resembles the PTD present in several
transducing proteins, including the HIV transactivating
protein Tat, the herpes simplex virus-1 (HSV-1) DNA-
binding protein VP22, and the Drosophila antennapedia
homeotic transcription factor ANTP (Loret et al., 1991;
Vives et al., 1997). While the fusion of these PTDs to
heterologous proteins has yielded a novel intracellular
delivery system (Anderson et al., 1993; Fawell et al., 1994;
Nagahara et al., 1998; Schwarze et al., 1999), it is not
known if any of the native proteins display biologically
important protein transduction properties in vivo. Per-
haps consistent with this finding, the function of the PTD
buried within Tat can be significantly improved by repo-
sitioning this domain at the amino-termini of heterolo-
gous proteins (Schwarze et al., 1999). Similarly, denatur-
ation of these transducing proteins also enhances their
intracellular delivery, likely by more efficiently exposing
the PTD (Bonifaci et al., 1995; Ho et al., 2001; Schwarze
and Dowdy, 2000). Taken together, these data raise the
issue of whether any of the known transducing proteins
are truly optimized for protein transduction in their native
state in vivo.
Vpr has been detected in the sera of HIV-infected
patients in quantities that correlate with degree of vire-
mia (Levy et al., 1994). Further, when added extracellu-
larly to the culture medium, both serum-derived and
partially purified recombinant Vpr protein preparations
activate HIV replication in latently infected T-cell lines,
monocyte cultures, and peripheral blood mononuclear
cells (PBMCs). These findings have led to the hypothesis
that extracellular Vpr can modulate virus replication in
vivo, but with no obvious mechanism (Levy et al., 1994,
1995). These studies provided the impetus for our inves-
tigation of the ability of extracellular Vpr to cross biolog-
ical membranes and effect changes in biological re-
sponses. Previously we demonstrated that Vpr could
enter cells, however, the mechanism and relevance of
such entry has not been established (Henklein et al.,
2000). Here we demonstrate that Vpr enters cells by
protein transduction and can subsequently effect G2
cell-cycle arrest and apoptosis, as well as rescue virus
production of Vpr-deficient HIV replicating within in-
fected macrophages when added in trans at nanomo-
lar concentrations. These data thus provide evidence for
a biological role for extracellular Vpr and protein trans-
duction.
RESULTS
Vpr is a transducing protein
Protein transduction is defined as rapid cellular uptake
of a protein occurring in an energy- and receptor-inde-
pendent manner (Frankel and Pabo, 1988; Green and
Loewenstein, 1988). While we previously showed that
sVpr is internalized by cells (Henklein et al., 2000), it was
not clear if this process reflected bona fide protein trans-
duction. Therefore, cellular uptake of sVpr was analyzed
under conditions of limited energy (4°C). FITC-trans-
ferrin, which is internalized by energy-dependent, recep-
tor-mediated endocytosis (Mellman, 1996), was analyzed
in parallel as a control similar to previous strategies
used to identify other transducing proteins (Derossi et
al., 1996). To determine the proportion of each peptide
internalized into cells versus that only bound at the cell
surface, the cells were treated with trypsin, which di-
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gests any trypsin-sensitive putative receptors. Incuba-
tion of cells with trypsin after exposure to sVpr or trans-
ferrin at 37°C showed little reduction in fluorescence
intensity, indicating that both of the proteins had moved
off the cell surface into a trypsin-resistant compartment
(data not shown). Conversely, when the cells were incu-
bated at 4°C to prevent receptor-mediated endocytosis
(Pastan and Willingham, 1981) and exposed to trypsin,
transferrin internalization was markedly reduced (indi-
cating successful removal of cell-surface receptors),
while entry of sVpr was unaffected (Fig. 1A). These find-
ings indicate that sVpr effectively enters cells under the
conditions of limited energy produced at 4°C. The differ-
ences observed for Vpr and transferrin internalization
suggest that Vpr entry does not involve receptor-medi-
ated endocytosis.
Full-length, native Vpr is required for effective
transduction
The transducing activity of HIV-1 Tat, Drosophila ANTP
(Joliot et al., 1998; Perez et al., 1992), and herpes simplex
virus VP22 (Elliott and O’Hare, 1997) proteins has been
mapped to highly basic PTDs. The PTD of Tat corre-
sponds to an 11 amino acid segment that can be fused
to heterologous proteins to facilitate their entry into cells
(Schwarze et al., 1999). The carboxy-terminal 73–96
amino acid region of Vpr contains an arginine-rich seg-
ment closely resembling the PTD present in Tat, VP22,
and ANTP. As a first step to mapping the transduction
domain within Vpr, we assessed the ability of synthetic
fragments of Vpr (amino acids 1–47, 52–96) to recapitu-
late the transducing activity of the full-length Vpr protein.
Neither the control 1–47 amino-terminal portion nor the
52–96 fragment of Vpr containing the arginine-rich seg-
ment exhibited detectable transducing activity (Fig. 1A).
Both of these Vpr fragments displayed low-level binding
to the cell surface that was partially removed by trypsin
treatment; however, this binding was no greater than that
obtained with the HIV-1 p6 protein and thus likely repre-
sents a low level of nonspecific interaction of these
proteins with the plasma membrane.
Studies with the PTD of Tat fused to heterologous
proteins have revealed that protein denaturation im-
proves transduction (Bonifaci et al., 1995; Schwarze et
al., 1999). Such denaturation may allow more effective
presentation of the PTD to the cell membrane (Derossi et
al., 1996). In this regard, transducing proteins may un-
dergo denaturation during their transit through the
plasma membrane and then undergo refolding within the
cell (Bonifaci et al., 1995; Schwarze et al., 1999). We next
assessed whether the efficiency of transduction of a
recombinant Vpr--galactosidase fusion protein was
similarly enhanced by urea denaturation. This construct
was used to show that the transduction properties were
not specific to Vpr and because similar experiments
were done with a Tat--galactosidase fusion protein
(Schwarze et al., 1999). 293T cells were incubated with
native or urea-denatured Vpr--galactosidase-FITC, and
uptake was then assessed by flow cytometry. To control
for nonspecific uptake, cells were incubated with a -ga-
lactosidase fusion protein containing the M9 nuclear
targeting signal that interacts with intracellular transpor-
tin (Jenkins et al., 1998). These studies revealed that the
Vpr--galactosidase fusion protein effectively entered
cells. However, urea denaturation of the Vpr--galacto-
sidase fusion protein markedly inhibited rather than en-
hanced such entry (Fig. 1B). These results suggest that
the Vpr PTD only functions effectively in the native struc-
ture conferred by the presence of the full-length Vpr
protein. Taken together, the data in Fig. 1 support the
notion that Vpr may be optimized for transduction in its
full-length, native state.
sVpr transduces multiple cell types rapidly and is
biologically active
Because of the lack of a requirement for specific
receptor engagement, transducing proteins are pre-
FIG. 1. Full-length sVpr exhibits protein-transducing activity. (A) 293T
cells were incubated with sVpr, synthetic fragments of Vpr correspond-
ing to amino acids 1–47 and 52–96, or control proteins transferrin and
p6Gag at 4°C followed by treatment with trypsin (closed bars) or medium
(open bars). Under the energy-limiting conditions of low temperature,
sVpr was taken up into a trypsin-resistant compartment (internalized),
whereas transferrin was not. In contrast to full-length Vpr, neither the
1–47 nor the 52–96 peptide (the latter spanning the entire candidate
PTD) mediated effective transduction. (B) 293T cells support transduc-
tion of native, but not urea-denatured, FITC-labeled Vpr--galactosi-
dase fusion proteins. M9-FITC protein was used as a negative control
in these studies.
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dicted to enter multiple cell types. When sVpr was incu-
bated with freshly isolated PBMCs, we observed efficient
uptake of sVpr, but not of the HIV p6Gag control, by CD4
and CD8 lymphocytes, CD14 macrophages, and the
entirety of the CD3 population (Fig. 2A). Additionally,
sVpr transduced the vast majority of Jurkat T cells in less
than 5 min (Fig. 2B). Together, these data indicate that
sVpr transduces a broad array of cells and that this
process proceeds with rapid kinetics.
When cells were incubated with graded concentra-
tions of fluorescently labeled sVpr, we observed a con-
centration-dependent increase in cell fluorescence con-
sistent with effective protein transduction (Fig. 3A). How-
ever, within the transduced cell population, we detected
a dose-dependent change in fluorescence that likely
reflects the uptake of different amounts of sVpr (Fig. 3B).
We further observed a nuclear pattern of expression of
Vpr, a finding that is consistent with the known karyo-
philic properties of this polypeptide (Henklein et al.,
2000). The interaction of Vpr with one or more compo-
nents of the nucleus may also explain why transduced
sVpr is not significantly transferred between cells under
culture conditions (data not shown).
Because Vpr induces G2 cell-cycle arrest, we com-
pared the degree of arrest within the transduced popu-
lation of cells, analyzing the DNA content of cells that
had accumulated various amounts of sVpr-Alexa 488.
Analysis of subpopulations of sVpr-transduced Jurkat T
cells revealed a dose-dependent induction of G2 arrest
(Figs. 3B and 3C). Specifically, 37% of the cells containing
the highest concentration of sVpr (gate III) displayed a
4N complement of DNA, compared to 33, 15.4, and 11%
of cells in gate II, gate I, and within the nontransduced
population, respectively. These findings indicate that
transduced sVpr induces G2 cell-cycle arrest, underscor-
ing the biological activity of such transduction.
Several studies have implicated Vpr in the induction of
apoptosis through a caspase-dependent mechanism
(Poon et al., 1998; Stewart et al., 1997, 1999, 2000; Yao et
al., 1998). Conversely some studies have suggested that
Vpr may inhibit programmed cell death (Conti et al.,
2000), while other studies have reconciled these differ-
ences revealing that Vpr induces early antiapoptotic and
late proapoptotic effects (Conti et al., 1998). To evaluate
the effects of sVpr protein transduction on apoptosis,
Jurkat T cells were incubated with sVpr and levels of
apoptosis were assessed by annexin V staining and
propidium iodide exclusion (Fig. 4A). Cultures incubated
with sVpr exhibited a significantly higher proportion of
annexin V staining cells over time than cultures incu-
bated in the absence of sVpr or with the p6Gag control
protein. These results are in agreement with earlier work
demonstrating that extracellular Vpr, in the absence of
other viral proteins, induces apoptosis (Huang et al.,
2000; Piller et al., 1998, 1999). Such effects of sVpr may
contribute to the pronounced bystander cell killing ob-
served in HIV-1-infected tissues in vivo (Finkel et al.,
1995).
Nuclear import of the HIV-1 PIC and infection of non-
dividing cells similar to macrophages is facilitated by the
karyophilic Vpr, p17 matrix, and integrase proteins as
well as by a triple-stranded DNA flap formed as an
intermediate of reverse transcription (for review, see
Sherman and Greene, 2002). Several prior studies have
demonstrated that HIV strains lacking Vpr are particu-
larly compromised in their ability to replicate in mono-
cyte-derived macrophages, possibly due to diminished
nuclear import of the viral PIC in these nondividing cells.
Therefore we examined whether extracellular sVpr could
be incorporated into virions during production. Indeed,
when NL4-3Vpr was generated from transfected plas-
mid DNA in the presence of graded amounts of sVpr, we
observed a dose-dependent incorporation into pelleted
virions (Fig. 4B). To determine whether transduction of a
highly purified preparation of Vpr can facilitate HIV rep-
lication in macrophages, sVpr (10 nM) was added to
monocyte-derived macrophage cultures infected with
FIG. 2. sVpr rapidly transduces multiple cell types. (A) PBMCs were
incubated with Cy3-sVpr (black bars) or Cy3-p6Gag (white bars) and
analyzed for expression of the indicated cell-surface markers. Flow
cytometric analysis revealed that CD4 and CD8 lymphocytes, CD14
monocytes, and CD3 cell types were all permissive to sVpr transduc-
tion. Significant uptake of a Cy3-p6Gag control protein was not detected
in any of these cell types. Error bars represent the mean  SD of
results obtained with cells from four random blood donors. (B) Jurkat T
cells were incubated with Cy3-labeled synthetic Vpr or p6Gag for various
times as indicated, and uptake was measured by flow cytometry. sVpr
uptake at 5 min occurred as efficiently as at 15 min and beyond.
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AD8, a macrophage-tropic molecular clone of HIV (Schu-
bert et al., 1995, 1999), or with AD8Vpr, an isogenic virus
lacking Vpr. AD8Vpr replicated poorly in macrophages;
however, the addition of sVpr to the medium restored
infectivity of this viral clone to near wild-type levels (Fig.
5). These results thus both confirm and extend the func-
tional properties of transduced sVpr.
DISCUSSION
Vpr is a conserved, multifunctional protein that en-
hances replication of HIV in macrophages and induces
G2 cell-cycle arrest in infected proliferating T cells, lead-
ing to enhanced LTR-dependent viral transcription. Cir-
culating Vpr has also been detected in the serum and
spinal fluid of HIV-infected patients at a concentration
that varies with the degree of p24 antigenemia (Levy et
al., 1994). It is, however, unknown whether such extra-
cellular forms of this protein are important for HIV repli-
cation or pathogenesis and, if so, how Vpr produces
these effects. Our studies now demonstrate that a highly
purified, synthetic preparation of Vpr exhibits protein
transduction properties, efficiently crossing cell mem-
branes at 4°C in a concentration-dependent but appar-
ently receptor-independent manner. The arginine-rich,
FIG. 3. Transduced sVpr induces G2 cell-cycle arrest in cells in a dose-dependent manner. (A) Jurkat T cells incubated with increasing amounts
of Alexa-488-labeled sVpr displayed dose-related increases in fluorescence. FL1-H represents the fluorescence height. (B) A histogram of transduced
cells divided into three arbitrary groups according to the (I) low, (II) intermediate, and (III) high level of transduction. (C) Cell-cycle analysis of the three
goups of sVpr-transduced cells reveals dose-dependent G2 cell-cycle arrest. Cells with the highest level of transduction displayed the greatest
accumulation of 4N DNA content. Lesser though highly significant effects on cell-cycle distribution were observed in cells with intermediate levels
of sVpr transduction.
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carboxy terminus of Vpr resembles the PTDs present in
other well-known transducing proteins. However, in con-
trast to the PTD present in these other transducing pro-
teins, a fragment of Vpr containing the isolated PTD of
Vpr was unable to mediate effective protein transduction.
Instead, the full-length Vpr protein was required for trans-
duction.
Of note, the Tat PTD functions more efficiently when
moved to the amino-terminus of Tat or fused to the
termini of heterologous proteins. Further, the PTD se-
quence can be optimized artificially both by the introduc-
tion of specific amino acid substitutions or by denatur-
ation (Schwarze et al., 2000). As such, the protein-trans-
ducing properties of the Tat PTD are clearly not
optimized for this function in the context of the native
protein. The central positioning of this domain may re-
flect requirements related to its RNA binding, nuclear
import, and transcription activities that involve this argi-
nine-rich motif. Nevertheless, full-length extracellular Tat
has various biological functions, including the enhance-
ment of interleukin-2 production in activated PBMCs (Ott
et al., 1997) and the induction of Kaposi’s sarcoma-like
lesions in mice (Ensoli et al., 1994). Indeed, these extra-
cellular functions of Tat have been exploited for vaccine
strategies in which Tat or a Tat toxoid serves as an
immunogen (Ensoli and Cafaro, 2000; Pauza et al., 2000).
In contrast to Tat, it is clear that wild-type Vpr is more
active for transduction than fragments containing the
putative PTD or full-length, denatured Vpr. Thus, it ap-
pears that the carboxy-terminal positioning of the Vpr
PTD in the context of the full-length, native Vpr protein
generates an effective transducing protein. Moreover,
such full-length Vpr proteins are biologically active when
transduced as evidenced by the induction of G2 cell-
cycle arrest and apoptosis and by the enhancement of
replication of Vpr-deficient viruses in human monocyte-
derived macrophages.
Bystander cell killing is a prominent feature of HIV-1-
infected tissues (Azad, 2000; Finkel et al., 1995; Xu et al.,
1997). Depending on the culture conditions, Vpr has been
shown to either increase or decrease apoptosis. Several
studies have suggested that recombinant formulations of
Vpr can induce cell death in a variety of cell types (Huang
et al., 2000; Piller et al., 1998, 1999). It is possible that
extracellular Vpr induces apoptosis by the formation of
ion-conductive membrane pores (Huang et al., 2000;
Piller et al., 1996, 1998, 1999) or even by mitochondrial
membrane permeation resulting in disruption of an ion
gradient and leading perhaps to release of cytochrome c
and activation of the caspase cascade (Ferri et al., 2000).
Attempts have been made to use peptides to map the
region of Vpr that induces cell death and results suggest
that the domain overlaps with an ion-channel-forming
phenotype (Piller et al., 1999). However, such mapping
experiments employing peptides or partially purified re-
combinant preparations of Vpr must be viewed with cau-
tion because full-length Vpr adopts different conforma-
tions depending on solution conditions such as pH and
the presence or absence of protein cofactors (Henklein
et al., 2000). Our studies now demonstrate that sVpr, in a
form that effectively transduces a broad array of target
cells and leads to the induction of G2 cell-cycle arrest,
can also induce a time-dependent apoptosis when incu-
bated with cultured cells. In one study, exposure to par-
tially purified Vpr induced differential apoptotic effects on
unstimulated (proapoptotic) versus CD3-stimulated (an-
tiapoptotic) PBMCs (Ayyavoo et al., 1997). However, this
study relied upon CD3 stimulation alone, a situation
inherently different from physiologic T-cell receptor (TCR)
signaling where coreceptors are also engaged (Cham-
bers and Allison, 1999). It is possible that Vpr influences
cells differentially dependent on various states such as
TCR activation or even infection (Conti et al., 2000). In
fact, it is known that fresh PBMCs from HIV-infected
FIG. 4. Transduced sVpr induces apoptosis and is incorporated into
virions. (A) Jurkat T cells were incubated with sVpr (open circles), p6Gag
(filled squares), or medium (filled circles) and assayed for apoptosis by
annexin V staining and propidium iodide (PI) exclusion. sVpr-induced
apoptosis was significantly increased after 48 h and peaked after 72 h.
Cells incubated with medium or p6Gag did not display similar increases
in annexin V staining. This experiment was repeated several times with
similar results. (B) Plasmid DNA from NL4-3Vpr was transfected in
293T cells in the presence or absence of graded amounts of sVpr. After
removal of cellular debris, viral lysates were ultracentrifuged at 40,000
g and the pellets resuspended in loading buffer prior to PAGE with
loading controlled by total virus input as measured by p24Gag. Wild-type
NL4-3 virions and hemaglutinin-Vpr (HA-Vpr) transfected cell lysates
were included as positive controls. Note the dose-dependent increase
in extracellular sVpr incorporation into virions.
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patients display a greater propensity for apoptosis upon
stimulation in vitro than PBMCs from HIV-seronegative
donors (Groux et al., 1992; Meyaard et al., 1992). Such
cell killing in vivo might reduce the effectiveness of
specific cytotoxic T lymphocytes targeting the virally in-
fected host cells. It will be interesting to determine if
serum Vpr contributes to this programmed cell death and
whether transducing Vpr participates as an effector in
the bystander cell killing observed in HIV infection.
HIV strains defective for Vpr cannot replicate efficiently
in macrophage cultures. This may reflect a contribution
of the nucleophilic Vpr protein within the PIC that facili-
tates HIV nuclear import in nondividing target cells such
as macrophages (Bukrinsky et al., 1992; Connor et al.,
1995; Heinzinger et al., 1994; Miller et al., 1997; Popov et
al., 1998). However, it is also possible that Vpr alters the
state of differentiation in these cells, producing a more
favorable host cell environment for viral replication (Sub-
bramanian et al., 1998). This important function of Vpr
may explain why this accessory protein is highly con-
served in vivo yet rapidly deleted in T-cell cultures (Goh
et al., 1998). Our findings show that sVpr enhances viral
replication when added in trans to macrophages infected
with Vpr-deficient strain of HIV. With the knowledge that
Vpr is present in serum and can transduce multiple cell
types including monocytes [Fig. 2 and previous work
(Henklein et al., 2000)], we now envision a scenario
where Vpr may be released locally in tissues after host
cell apoptosis. Such circulating forms of Vpr might in turn
transduce macrophages targeted for infection and thus
facilitate nuclear import of the HIV PIC. In fact, sVpr can
be incorporated into virions when it is present in medium
during production of viral stocks in transfected cells (Fig.
4B). Alternatively, since the role of PIC import by Vpr has
been questioned (Bouyac-Bertoia et al., 2001), it is pos-
sible that Vpr-transduced macrophages may be activated
or differentiated in a manner that facilitates subsequent
viral infection and replication (Subbramanian et al.,
1998). The fact that sVpr is incorporated into virions does
not rule out the possibility that Vpr can transactivate
replication in a virion-free form. In fact, in monocyte-
derived macrophages infected with wild-type virus infec-
tion of MDM there was a slight decrease in viral produc-
tion in the presence of sVpr, implying a possible balance
between transactivation and toxicity.
In summary, our findings implicate Vpr as an effective
transducing protein. These transducing properties of Vpr
may project certain effects of HIV infection to uninfected
bystander cells, thus contributing to viral pathogenesis.
Indeed, it is intriguing that HIV encodes two proteins, Vpr
and Tat, that display transducing properties. These pro-
teins likely act not only intracellularly but also extracel-
lularly in a manner that promotes more efficient growth
and spread of HIV-1. Whether disruption of the extracel-
lular function of Vpr would be of therapeutic benefit
remains to be explored.
MATERIAL AND METHODS
Protein synthesis
sVpr and relevant fragments were synthesized, puri-
fied, and characterized as described (Henklein et al.,
FIG. 5. Addition of sVpr to the extracellular medium enhances replication in HIV-1 Vpr-infected macrophages. Monocyte-derived human
macrophages were infected with wild-type (A) or Vpr (B–D) AD8 macrophage-tropic viruses and were additionally incubated with mock (open circles)
or sVpr-containing (filled circles) medium. Viral replication, as measured by reverse transcriptase (RT) activity, was elevated in those cultures
complemented with sVpr (10 nM).
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2000). The 52 amino acid p6Gag protein comprising the
carboxy-terminal mature processing product of the
Pr55Gag precursor derived from the isolate HIV-1NL-43
(Adachi et al., 1986) was synthesized in an analogous
fashion. The purity of peptides was verified by reverse-
phase high-performance liquid chromatography. sVpr
was additionally characterized by amino-terminal se-
quencing with an Applied Biosystems 473A pulsed-liq-
uid-phase sequencer and by positive-ion electrospray
ionization mass spectroscopy performed with a fixed
Finnigan LCQ ion trap mass spectrometer equipped with
an electrospray source as described (Henklein et al.,
2000). Matrix-assisted laser desorption/ionization time-
of-flight (MALDI-TOF) mass spectra were recorded on a
Bruker reflex MALDI-TOF mass spectrometer using an
N2 laser (337 nm). sVpr or derived peptides were fluo-
rescently labeled by using a modification of the Alexa
488 labeling kit (A-10235, Molecular Probes) or were
end-labeled with a Cy3-like fluorophore (Henklein et al.,
2000).
Cell culture
293T cells were cultured in Dulbecco’s modified Ea-
gle’s medium (DMEM) (Life Technologies). Jurkat T cells
were cultured in RPMI 1640. Both media were supple-
mented with 10% fetal bovine serum, 2 mM L-glutamine,
100 U/ml penicillin G, and 100 g/ml streptomycin.
PBMCs from HIV-seronegative random healthy blood do-
nors were obtained from the Stanford Blood Bank (Palo
Alto, CA). PBMCs were purified on Ficoll–Paque density
gradients (Amersham).
sVpr entry assay
293T cells at 80% confluency were preincubated at
4°C for 30 min followed by incubation in DMEM with
either 30 g/ml (2.63 M) sVpr-Cy3, 50 ng/ml transferrin-
polylysine FITC (Sigma) or medium alone for 30 min at 4
or 37°C. Cells were then washed once with ice-cold
phosphate-buffered saline (PBS) and incubated with ice-
cold 0.5% trypsin EDTA or DMEM for 30 min. Trypsin
cleavage was halted by adding 3 vol of ice-cold DMEM.
Cells were washed once in ice-cold PBS, and fluores-
cence uptake was measured with a FACScan flow cy-
tometer (Beckton–Dickinson). Because the background
fluorescence was altered with temperature and trypsin
treatment, the mean fluorescence of the transduced pop-
ulations (reported as the relative geometric mean of
fluorescence) was measured and normalized by sub-
tracting background values obtained in mock-treated
control cells.
Cell-type independent uptake and cell-cycle assays
Jurkat T cells were incubated with sVpr-Alexa 488 (30
g/ml) or control synthetic p6Gag-Alexa 488 (30 g/ml) in
RPMI for 30 min at 37°C. Cells were washed three times
with PBS and analyzed by flow cytometry. Uptake was
measured as the percentage of cells displaying greater
fluorescence than cells treated with p6Gag-Alexa 488.
PBMCs from four donors were each incubated with sVpr-
Alexa 488 (30 g/ml) or control synthetic p6Gag-Alexa 488
(30 g/ml) in RPMI for 30 min at 37°C, washed three
times with PBS, and stained alone or in combination with
CD4-phycoerythrin (PE), CD8-PE, CD3-APC (Beckton–
Dickinson), and/or CD14-PE (Pharmingen) fluorescently
labeled antibodies. Compensation was employed to en-
sure proper separation of adjacent fluorescence chan-
nels. Cell-cycle analysis was performed on Jurkat T cells
after incubation with sVpr-Cy3 for 48 h and fixation in a
2% formaldehyde solution followed by incubation with 1
mg/ml RNaseA and 10 g/ml To-Pro-3 (Molecular
Probes) in PBS for 30 min. Cellular DNA content in the
fixed cells was then assessed with a FACScan flow
cytometer and analyzed with FlowJo Software (Treestar).
Urea denaturation
Vpr--galactosidase conjugated to FITC and M9-FITC
were produced as described (Jenkins et al., 1998) and
incubated in 4 M urea with 20 M HEPES for 30 min,
followed by a dialysis through a 10,000 molecular weight
cutoff Slide-A-Lyzer dialysis cassette (Pierce, Rockford,
IL) with PBS for 6 h at room temperature.
Apoptosis assay
Jurkat T cells were incubated with 30 g/ml sVpr-Alexa
488 for the indicated number of days. Medium containing
the indicated peptide was exchanged every 72 h. For
analysis, cells were incubated with a 1:50 dilution of
antiannexin PE and 1 g/ml propidium iodide (Molecular
Probes) in buffer A (calcium/magnesium-free PBS with
1.25 mM CaCl2, and 2% fetal bovine serum). Cells were
washed once with buffer A and analyzed for fluores-
cence by flow cytometry. Annexin PE-positive, propidium
iodide-negative cells were scored as apoptotic.
Virus production and monocyte isolation/infection
Infection experiments were performed with the HIV-1
chimera NL4-3(AD8) (Freed and Martin, 1994). This che-
mokine receptor 5-dependent viral strain carries the
KpnI-BsmI env determinant of AD8 and the V3 loop from
a primary monocyte-tropic isolate (Theodore et al., 1996)
inserted into pNL4-3 (Adachi et al., 1986). The Vpr-defi-
cient mutant pNL(AD8)-R was generated from pNL4-
3(AD8) by digestion with EcoRI and blunting the resultant
“overhangs” with DNA-polymerase I to generate a frame-
shift mutation in the Vpr open reading frame.
Monocytes isolated from blood obtained by leuko-
pheresis from HIV-seronegative donors were elutriated,
precultured, and differentiated as described (Ehrenreich
et al., 1993; Schubert et al., 1995, 1999). Cells were
resuspended in DMEM at a concentration of 0.5  106
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cells/ml, and 1.5 ml of cell suspension was replated into
24-well tissue culture plates (Nunc); the cells were al-
lowed to adhere, and then infected with HIV within 3
days.
Viral stocks were prepared by transfecting HeLa cells
with pNL(AD8)-R or pNL(AD8) plasmids. For transfec-
tions, HeLa cells were grown to near confluency in 75-
cm2 flasks (5  107 cells per flask). Two hours before
transfection, the medium was replaced with 15 ml of
fresh DMEM, and cells were transfected with lipo-
fectamine 2000 (Life Technologies). Virus-containing su-
pernatants were clarified by centrifugation at 1000 g for
5 min and filtered through a 0.45-m filter to remove
residual cells and debris. Virions were pelleted by ultra-
centrifugation in a Beckman SW55 rotor (1 h at 35,000
rpm), resuspended in RPMI1640/fetal bovine serum, and
sterilized by filtration. The viral stocks were assayed for
reverse transcriptase activity by 32P-TTP incorporation
with an oligo(dT)-poly(A) template as described (Willey et
al., 1988). Routinely, 106 reverse transcriptase units were
used to infect 106 monocyte-derived macrophages. After
15 h of incubation with virus, the medium was removed
and replaced with virus-free medium. The infection sta-
tus of the cultures was monitored by determining the
reverse transcriptase activity in the medium. The cul-
tures were also examined by light microscopy for syncy-
tia formation and scored by counting the number of
multinucleated cells per field.
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